Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594410 | 0.93 | VCP (0.43) | VCPHRH3DAOCYP2D6KCNH2 | |
| SCHEMBL20234593 | 0.92 | VCP (0.36) | VCPHRH3ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL20046477 | 0.88 | VCP (0.44) | VCPHRH3DAOCYP2D6KCNH2 | |
| SCHEMBL24926150 | 0.87 | VCP (0.33) | VCPALDH1A1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL24926050 | 0.87 | VCP (0.34) | VCP | |
| SCHEMBL21899200 | 0.86 | VCP (0.41) | VCPHRH3DAOCYP2D6KCNH2 | |
| SCHEMBL9611075 | 0.86 | GNAO1 (0.34) | DRD2DRD3 | |
| SCHEMBL21214914 | 0.85 | HRH3 (0.36) | VCPHRH3CYP2D6KCNH2 | |
| SCHEMBL22603537 | 0.84 | HRH3 (0.43) | VCPHRH3CYP2D6KCNH2 | |
| SCHEMBL24926120 | 0.83 | VCP (0.38) | VCPHRH3DAOCYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | VCP 415/4885HRH3 3443/4885ALDH1A1 3804/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | VCP 430/4885HRH3 3674/4885ALDH1A1 4172/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | VCP 430/4885HRH3 3674/4885ALDH1A1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.